Merck News Item

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first.

These product press releases are intended for use in the United States only. Countries outside of the U.S. may have different regulatory requirements and review practices that may require referencing different information.

27 Jun 2008	Schering-Plough And Merck Announce Withdrawal of Loratadine/Montelukast NDA and Termination of Respiratory Joint Venture

27 Jun 2008	Merck's Investigational Migraine Treatment Telcagepant Improved Pain and Migraine-Associated Symptoms in Phase III Study

20 Jun 2008	Merck Provides Update on U.S. Regulatory Status of MK-0524A (ER niacin/laropiprant) and MK-0524B (ER niacin/laropiprant/simvastatin)

27 May 2008	Odanacatib, Merck's Investigational Cathepsin K Inhibitor, Reduced Markers of Bone Turnover in Women with Breast Cancer and Bone Metastases

21 May 2008	ACHIEVE Imaging Study Discontinued

28 Apr 2008	Merck Receives Not Approvable Letter from FDA for MK-0524A (ER niacin/laropiprant)

25 Apr 2008	Schering-Plough/Merck Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast

24 Apr 2008	Two Merck Medicines Recommended for Approval in the European Union

17 Apr 2008	Dynavax and Merck & Co., Inc. Update Status of Clinical Hold of Investigational Vaccine HEPLISAV™

01 Apr 2008	Merck's Investigational Rolofylline Associated with Improved Dyspnea and Preserved Renal Function in Acute Heart Failure Patients in a Phase III Pilot Study

31 Mar 2008	Update on ACHIEVE: A Study of Merck's Investigational Extended-Release Niacin/Laropiprant (CORDAPTIVE™)

31 Mar 2008	Phase III Data Showed Taranabant, Merck's Investigational Medicine to Treat Obesity, Led to Statistically Significant Weight Loss

31 Mar 2008	Patients Treated with Merck's Investigational Extended-Release Niacin/Laropiprant (CORDAPTIVE™) Reported Significantly Less Flushing Than Patients Treated with Niaspan™ in Phase III Study

17 Mar 2008	Merck Scientists Apply Innovative Research Method to Identify Changes in Gene Networks Linked to Obesity Studies Published in Nature

17 Mar 2008	Dynavax and Merck & Co., Inc. Report Clinical Hold of Investigational Vaccine HEPLISAV

top